0.676
price down icon3.57%   -0.025
after-market アフターアワーズ: .68 0.004 +0.59%
loading
前日終値:
$0.701
開ける:
$0.71
24時間の取引高:
3.36M
Relative Volume:
1.83
時価総額:
$123.99M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-0.463
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-18.29%
1か月 パフォーマンス:
-43.19%
6か月 パフォーマンス:
-42.71%
1年 パフォーマンス:
+0.90%
1日の値動き範囲:
Value
$0.6618
$0.72
1週間の範囲:
Value
$0.6618
$0.8565
52週間の値動き範囲:
Value
$0.6303
$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1183)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
137
Name
Twitter
@nektarnews
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
0.676 123.99M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 122.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 78.30B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.73B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.47B 3.30B -501.07M 1.03B -2.1146

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
04:37 AM

Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com

04:37 AM
pulisher
08:30 AM

Chutes & Ladders—J&J vet jumps to Affinia - Fierce Biotech

08:30 AM
pulisher
Feb 06, 2025

Nektar Therapeutics Sees Unusually High Options Volume (NASDAQ:NKTR) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Nektar Therapeutics announces senior leadership change - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

Nektar Names Kotzin Interim Chief Medical Officer - MarketWatch

Feb 04, 2025
pulisher
Feb 04, 2025

Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, - openPR

Feb 04, 2025
pulisher
Feb 03, 2025

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance

Feb 03, 2025
pulisher
Jan 26, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by HB Wealth Management LLC - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

B. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation - MSN

Jan 25, 2025
pulisher
Jan 25, 2025

JPMorgan Chase & Co. Buys 606,057 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

JPMorgan Chase & Co. Grows Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

Jan 25, 2025
pulisher
Jan 22, 2025

Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan

Jan 22, 2025
pulisher
Jan 18, 2025

Barclays PLC Purchases 175,596 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Phase 2b study of rezpegaldesleukin for atopic dermatitis reaches target enrollment - Healio

Jan 17, 2025
pulisher
Jan 17, 2025

Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08 - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

B-Cell Lymphoma Clinical and Non-Clinical Studies, Key - openPR

Jan 16, 2025
pulisher
Jan 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stake Lifted by Jane Street Group LLC - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times

Jan 13, 2025
pulisher
Jan 13, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 11, 2025

Analysts Issue Forecasts for NKTR FY2024 Earnings - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Nektar hits enrollment target for atopic dermatitis study By Investing.com - Investing.com Australia

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin - Dermatology Times

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar hits enrollment target for atopic dermatitis study - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study - StreetInsider.com

Jan 10, 2025
pulisher
Jan 10, 2025

Nektar's Key Atopic Dermatitis Drug Trial Hits Full Enrollment Ahead of Schedule - StockTitan

Jan 10, 2025
pulisher
Jan 09, 2025

Nektar Therapeutics to sell Alabama facility to Ampersand - MSN

Jan 09, 2025
pulisher
Jan 09, 2025

B. Riley Upgrades Nektar Therapeutics (NASDAQ:NKTR) to Strong-Buy - MarketBeat

Jan 09, 2025
pulisher
Jan 08, 2025

Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at B. Riley - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor - Investing.com India

Jan 08, 2025
pulisher
Jan 07, 2025

B.Riley Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider.com

Jan 07, 2025
pulisher
Jan 07, 2025

Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance

Jan 07, 2025
pulisher
Jan 06, 2025

12 Best Penny Stocks to Invest in According to the Media - Insider Monkey

Jan 06, 2025
pulisher
Jan 05, 2025

Numerous Nektar Therapeutics Insiders Sold Stock: Not A Positive Omen - Simply Wall St

Jan 05, 2025
pulisher
Jan 04, 2025

Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership - Yahoo Finance

Jan 04, 2025
pulisher
Dec 28, 2024

Nektar Therapeutics chief legal officer sells shares worth $44,800 By Investing.com - Investing.com Nigeria

Dec 28, 2024
pulisher
Dec 26, 2024

Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 Shares - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Nektar Therapeutics chief legal officer sells shares worth $44,800 - Investing.com

Dec 26, 2024
pulisher
Dec 21, 2024

Why Nektar Therapeutics May Be About to Take Off - AOL

Dec 21, 2024
pulisher
Dec 21, 2024

Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com - Investing.com Australia

Dec 21, 2024
pulisher
Dec 20, 2024

Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in Stock - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Nektar Therapeutics chief R&D officer sells $48,048 in stock - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Howard W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 19, 2024

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock - Investing.com India

Dec 19, 2024

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Wilson Mark Andrew
Chief Legal Officer
Dec 24 '24
Sale
0.89
16,560
14,738
335,332
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
大文字化:     |  ボリューム (24 時間):